Literature DB >> 16687939

Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome.

Raphaelle Dumaine1, C Michael Gibson, Sabina A Murphy, Matthew Southard, Hung Q Ly, Carolyn H McCabe, Robert P Giugliano, Christopher P Cannon, Elliott M Antman, Eugene Braunwald.   

Abstract

Chronic hypertension is a well established risk factor for the development of cardiovascular disease; however, its prognostic significance after a non-ST-segment elevation acute coronary syndrome remains to be established. Data from 15,414 patients included in six randomized Thrombolysis in Myocardial Infarction (TIMI) trials (TIMI 3B, TIMI 11A, TIMI 11B, TIMI 12, the Orbofiban in Patients With Unstable Coronary Syndromes [OPUS]-TIMI 16, and the Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy [TACTICS]-TIMI 18) were analyzed. A history of hypertension was present in 10,998 (71.35%) patients; comorbidities and higher TIMI risk scores were more likely in these patients. However, positive troponin and ST-segment deviations were less frequent among hypertensive patients. After multivariate analysis, the history of hypertension was associated with more adverse outcomes, specifically the composite end point of death/myocardial infarction at 30 days and 1 year (odds ratio [OR] 1.54, 95% confidence interval [CI] 1.31-1.81; p<0.001 at 1 year) than in patients without this history. An independent relationship was also observed with mortality (OR 1.70, 95% CI 1.34-2.16; p<0.001 at 1 year), myocardial infarction (OR 1.50, 95% CI 1.23-1.82; p<0.001 at 1 year), recurrent ischemia (OR 1.24, 95% CI 1.11-1.38; p<0.001 at 1 year), and major bleeding (OR 1.45, 95% CI 1.03-2.06; p=0.036 at 30 days). It was concluded that chronic hypertension remains an independent marker for major short- and long-term cardiac adverse outcomes after non-ST-segment elevation acute coronary syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687939      PMCID: PMC8109650          DOI: 10.1111/j.1524-6175.2006.05384.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  28 in total

1.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.

Authors:  E M Antman; M Cohen; P J Bernink; C H McCabe; T Horacek; G Papuchis; B Mautner; R Corbalan; D Radley; E Braunwald
Journal:  JAMA       Date:  2000-08-16       Impact factor: 56.272

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

4.  Intermittent claudication. A risk profile from The Framingham Heart Study.

Authors:  J M Murabito; R B D'Agostino; H Silbershatz; W F Wilson
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

Review 5.  Atherosclerosis and hypertension: mechanisms and interrelationships.

Authors:  V J Dzau
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

6.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.

Authors:  E Boersma; K S Pieper; E W Steyerberg; R G Wilcox; W C Chang; K L Lee; K M Akkerhuis; R A Harrington; J W Deckers; P W Armstrong; A M Lincoff; R M Califf; E J Topol; M L Simoons
Journal:  Circulation       Date:  2000-06-06       Impact factor: 29.690

7.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

Authors:  C P Cannon; C H McCabe; R G Wilcox; A Langer; A Caspi; P Berink; J Lopez-Sendon; J Toman; A Charlesworth; R J Anders; J C Alexander; A Skene; E Braunwald
Journal:  Circulation       Date:  2000-07-11       Impact factor: 29.690

8.  Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study.

Authors:  D Levy; P W Wilson; K M Anderson; W P Castelli
Journal:  Am Heart J       Date:  1990-03       Impact factor: 4.749

Review 9.  Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?

Authors:  G Y Lip; D C Felmeden; F L Li-Saw-Hee; D G Beevers
Journal:  Eur Heart J       Date:  2000-10       Impact factor: 29.983

10.  TIMI frame count: a quantitative method of assessing coronary artery flow.

Authors:  C M Gibson; C P Cannon; W L Daley; J T Dodge; B Alexander; S J Marble; C H McCabe; L Raymond; T Fortin; W K Poole; E Braunwald
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

View more
  7 in total

1.  Impact of hypertension on short- and long-term prognoses in patients with ST elevation myocardial infarction and without previously known diabetes.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Paola Attanà; Claudio Picariello; Gian Franco Gensini
Journal:  Heart Vessels       Date:  2011-07-07       Impact factor: 2.037

2.  Impact of hypertension history on short and long-term prognosis in patients with acute myocardial infarction treated with percutaneous angioplasty: comparison between STEMI and NSTEMI.

Authors:  Emanuele Cecchi; Maria Grazia D'Alfonso; Marco Chiostri; Elena Parigi; Daniele Landi; Serafina Valente; Salvatore Mario Romano; Gian Franco Gensini; Cristina Giglioli
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-11-12

Review 3.  Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective.

Authors:  Konstantinos Konstantinou; Costas Tsioufis; Areti Koumelli; Manos Mantzouranis; Alexandros Kasiakogias; Michalis Doumas; Dimitris Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-12       Impact factor: 3.738

4.  The impact of hypertension on patients with acute coronary syndromes.

Authors:  Claudio Picariello; Chiara Lazzeri; Paola Attanà; Marco Chiostri; Gian Franco Gensini; Serafina Valente
Journal:  Int J Hypertens       Date:  2011-06-22       Impact factor: 2.420

5.  Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Mohamed S Awad; Sinan B Alrifai
Journal:  Indian J Endocrinol Metab       Date:  2016 Jan-Feb

6.  Impact of Admission Systolic Blood Pressure and Antecedent Hypertension on Short-Term Outcomes After ST-Segment Elevation Myocardial Infarction: Strobe-Compliant Article.

Authors:  Wenfang Ma; Yan Liang; Jun Zhu; Yanmin Yang; Huiqiong Tan; Litian Yu; Xin Gao; Guangxun Feng; Jiandong Li
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

7.  Risk Stratification and in Hospital Morality in Patients Presenting with Acute Coronary Syndrome (ACS) in Bahrain.

Authors:  Taysir S Garadah; Khalid Bin Thani; Leena Sulibech; Ahmed A Jaradat; Mohamed E Al Alawi; Haytham Amin
Journal:  Open Cardiovasc Med J       Date:  2018-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.